Pyrimidine compounds as antagonists of SRS-A

ABSTRACT

Compounds of formula I 
&lt;CHEM&gt;
 and salts thereof are useful for the treatment and prophylaxis of allergic diseases. Production and use of the compounds is described.

This is a division of application Ser. No. 173,734 now, U.S. Pat. No.4,855,310 filed Mar. 25, 1988, which is a Continuation-in-Part of U.S.Ser. No. 796,628 filed Nov. 8, 1985, now abandoned.

FIELD OF THE INVENTION

This invention relates to novel heterocyclic compounds shown by thefollowing general formula (I) and the salts thereof useful asmedicaments, in particular as antagonist of slow reacting substance ofanaphylaxis (SRS-A), and also a process of producing them; ##STR2##wherein, R¹ represents a lower acyl group; R² represents a lower alkylgroup; A represents a lower alkylene group which may be substituted by ahydroxy group; Y represents an oxygen atom, a sulfur atom, acarbonylimino group (--CONH--), or an iminocarbonyl group (--NHCO--);Het represents a 5- or 6-membered heterocyclic ring having 1 to 3 heteroatoms selected from the group consisting of oxygen sulfur and nitrogensaid heterocyclic ring may be fused with a benzene ring; R³, R⁴ and R⁵,which may be the same or different, each represents a hydrogen atom, alower alkyl group, a group shown by formula --A¹ --R⁶ (wherein, A¹represents a lower alkylene group and R⁶ represents a hydroxy group, amercapto group, a carboxy group, or a lower alkoxycarbonyl group), ahydroxy group, a mercapto group, a lower alkoxy group, a lower alkylthiogroup, a group shown by formula --Y¹ --A² --R⁷ (wherein, Y¹ representsan oxygen atom or a sulfur atom; A² represents a lower alkylene group;and R⁷ represents a carboxy group, a lower alkoxycarbonyl group, ahydroxyaminocarbonyl group, a mono-or a di-lower alkylaminocarbonylgroup, or an N-lower alkyl hydroxyaminocarbonyl group), an oxo group(═O), a thioxo group (═S), an amino group, a group shown by formula--NH--R⁸ (wherein, R⁸ represents a carboxy lower alkyl group or a loweralkoxycarbonyl lower alkyl group), a group shown by formula --NH--CO--R⁹(wherein, R⁹ represents a carboxy lower alkyl group, a loweralkoxycarbonyl lower alkyl group, a lower alkoxyphenyl loweralkoxycarbonyl lower alkyl group, a carboxy group, or a loweralkoxycarbonyl group), a carboxy group, or a group shown by formula--CO--R¹⁰ (wherein, R¹⁰ represents a lower alkoxy group); however, whenHet is a heterocyclic ring fused with a benzene ring, Y is bonded to theheterocyclic ring.

BACKGROUND OF THE INVENTION

It is generally considered that in allergic asthma and other atopicdiseases of man or anaphylactic shock in animals, various chemicalmediators are released from lung and other tissues and causedifficulties in living bodies, such as the constriction of smoothmuscles, e.g. bronchi, pulmonary artery, etc., and the enhancement ofvascular permeability in the skin. As such chemical mediators, there arehistamine and SRS-A. Histamine plays an important role in guinea piganaphylactic shock but not in allergic asthma in man (Eiser,"Pharmacology and Therapeutics", 17, 239-250 (1982)), whereas a numberof evidences suggest that SRS-A is the most important chemical mediatorof allergic asthma in man (Brocklehurst, "Journal of Physiology", 151,416-435(1960); Austen and Orange, "American Review of RespiratoryDiseases", 12, 423-436(1975); Adams and Lichtenstein, "Journal ofImmunology", 122, 555-562(1979)).

The development of the medicaments for prophylaxis, elimination andreduction of immediate hypersensitivity reactions was performed aimingat inhibiting the production and release of such chemical mediators orantagonizing the action, of these chemical mediators. As an inhibitor ofhistamine release, disodium cromoglycate is well known and as aninhibitor of actions induced by histamine, various anti-histamines arecommercially available. On the other hand, SRS-A is known as a slowreactive and long acting chemical mediator while histamine is a rapidacting and short acting chemical mediator, and it has recently beenrecognized that SRS-A is a mixture of Leukotriens C₄, D₄ and E₄ thestructure of which have been clarified by Dr. Samuelsson. SRS-A, i.e.,Leukotriens are lipoxigenase products of polyunsaturated fatty acids (inparticular, arachidonic acid) and it has been reported that SRS-A hasvarious activities such as enhancement of mucus production, reduction ofmucociliary transport, coronary artery constrictor action, reduction ofcardiac contractility, etc., besides the aforesaid action in thecharacter of chemical mediator in immediate hypersensitivity reactions.

To delineate the dynamic roles of SRS-A and to modulate its actions invarious phthological conditions, obviously it would be highly desirableto have a specific and in vivo active receptor antagonist. Furthermore,it is clinically desirable to prepare an orally active compound. FPL55712* of Fisons shows potent anti-SRS-A activity in isolated tissues(Augstein et al, Nature New Biol., 245, 215-217(1973)). However, itsbiological half life is very short and its absorption by oral route isvery poor (Sheard et al, Mongr. Allergy, 12, 245-249(1977)). ##STR3##

Accordingly, it has been desired to develop medicaments capable ofinhibiting the production and release of SRS-A or medicaments capable ofantagonizing these actions of SRS-A, in particular, the aforesaidmedicaments effective in oral administration.

SUMMARY OF THE INVENTION

As the result of investigations for developing medicaments capable ofinhibiting the production and release of SRS-A or medicaments capable ofantagonizing the actions of SRS-A, the inventors have discovered thatthe compounds shown by general formula (I) described above and the saltsthereof strongly antagonize the actions of SRS-A, are effective in oraladministration, and shown very weak toxicity, and the inventors havesucceeded in accomplishing this invention based on the discovery.

The feature of the compound of this invention in chemical structure ison the point that a 5- or 6-membered heterocyclic ring having 1 to 3hetero atoms is directly bonded to the terminal of the compound. Thatis, the compound of this invention has the chemical structural feature,as shown in the formula (I), ##STR4## in the point that moiety (c) is a5- or 6-membered heterocyclic ring having 1 to 3 hetero atoms and theheterocyclic ring is directly bonded to moiety (b).

Hitherto, in relation to the compounds of this invention, variouscompounds are known as, for example, above-described FPL 55712 of Fisonsand as described in, for example, U.K. Pat. No. 2,058,785. The U.K.patent discloses the compounds shown by the following the generalformula; ##STR5## On these compounds, moiety (c) is a benzene ring or abenzene ring to which a heterocyclic ring is condensed and in each casethe benzene ring is directly bonded to moiety (b). That is, compoundswherein the moiety (c) is a heterocyclic ring as the compounds of thisinvention are scarcely known. A tetrazole is reported in (JapanesePatent Publication (Unexamined) No. 164,344/84.

DETAILED DESCRIPTION OF THE INVENTION

The term "lower" in this specification means a straight or branchedcarbon chain of 1 to 6 carbon atoms.

Accordingly, the "lower alkyl group" includes a methyl group, an ethylgroup, a propyl group, an isopropyl group, a butyl group, an isobutylgroup, a sec-butyl group, a tert-butyl group, a pentyl group, anisopentyl group, a neopentyl group, a tert-pentyl group, a 1-methylbutylgroup, a 2-methylbutyl group, a 1,2-dimethylpropyl group, a hexyl group,an isohexyl group, a 1-methylpentyl group, a 2-methylpentyl group, a3-methylpentyl group, a 1,1-dimethylbutyl group, a 1,2-dimethylbutylgroup, a 2,2-dimethylbutyl group, a 1,3-dimethylbutyl group, a2,3-dimethylbutyl group, a 3,3-dimethylbutyl group, a 1-ethylbutylgroup, a 2-ethylbutyl group, a 1,1,2-trimethylpropyl group, a1,2,2-trimethylpropyl group, a 1-ethyl-1-methylpropyl group, a1-ethyl-2-methylpropyl group, etc.

Also, the "lower acyl group" includes a formyl group, an acetyl group, apropionyl group, a butyryl group, an isobutyryl group, a valeryl group,an isovaleryl group, a pivaloyl group, a hexanoyl group, etc.

Furthermore, the "lower alkylene group" includes straight chain orbranched alkylene groups having 1 to 6 carbon atoms, such as a methylenegroup, an ethylene group, a methylmethylene group ##STR6## atrimethylene group, a 1-methylethylene group ##STR7## a 2-methylethylenegroup ##STR8## a tetramethylene group, a 1-methyltrimethylene group, a2-methyltrimethylene group, a 3-methyltrimethylene group, a1-ethylethylene group, a 2-ethylethylene group, a pentamethylene group,a 1-methyltetramethylene group, a 2-methyltetramethylene group, a3-methyltetramethylene group, a 4-methyltetramethylene group, ahexamethylene group, etc. Practical examples of the "lower alkylenegroup" substituted by a hydroxy group are hydroxy lower alkylene groupsthat a hydrogen atom at an optional position of the above-described"lower alkylene group" is substituted by a hydroxy group, such ashydroxymethylene group, a 1-hydroxyethylene group, a 2-hydroxyethylenegroup, a 1-hydroxytrimethylene group, a 2-hydroxytrimethylene group, a3-hydroxytrimethylene group, a 1-hydroxy-2-methylethylene group, a2-hydroxy-1-methlethylene group, a 1-hydroxytetramethylene group, a2-hydroxytetramethylene group, a 3-hydroxytetramethylene group, a4-hydroxytetramethylene group, a 2-hydroxy-1-methyltrimethylene group, a2-hydroxy-3-methyltetramethylene group, a 2-hydroxypentamethylene group,a 4-hydroxypentamethylene group, a 2-hydroxyhexamethylene group, a5-hydroxyhexamethylene group, etc.

Also, the "lower alkoxy group" includes straight chain or branchedalkoxy groups having 1 to 6 carbon atoms, such as a methoxy group, anethoxy group, a propoxy group, an isopropoxy group, a butoxy group, anisobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxygroup, an isopentyloxy group, a neopentyloxy group, a tert-pentyloxygroup, a hexyloxy group, etc.

The "lower alkylthio group" are straight chain or branched alkylthiogroups having 1 to 6 carbon atoms and includes a methylthio group, anethylthio group, a propylthio group, an isopropylthio group, a butylthiogroup, an isobutylthio group, a sec-butylthio group, a tert-butylthiogroup, a pentylthio group, an isopentylthio group, a neopentylthiogroup, a tertpentylthio group, a hexylthio group, etc.

The "lower alkoxycarbonyl groups" is the groups ester-formed by straightchain or branched alcohols having 1 to 6 carbon atoms and carboxy groupand includes a methoxycarbonyl group, an ethoxycarbonyl group, apropoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonylgroup, an isobutoxycarbonyl group, a sec-butoxycarbonyl group, atertbutoxycarbonyl group, a pentyloxycarbonyl group, anisopentyloxycarbonyl group, a neopentyloxycarbonyl group, atert-pentyloxycarbonyl group, a hexyloxycarbonyl group, etc.

Also, the term "mono- or di-lower alkylaminocarbonyl group" means anaminocarbonyl group of which one or two hydrogen atoms are substitutedby the abovedescribed "lower alkyl group". Practical examples of themare a monoalkylaminocarbonyl group substituted by a straight chain orbranched alkyl group having 1 to 6 carbon atoms, such asmethylaminocarbonyl group, an ethylaminocarbonyl group, apropylaminocarbonyl group, an isopropylaminocarbonyl group, abutylaminocarbonyl group, an isobutylaminocarbonyl group, apentylaminocarbonyl group, an isopentylaminocarbonyl group, ahexylaminocarbonyl group, etc.; a symmeteric dialkylaminocarbonyl groupsubstituted by a straight chain or branched alkyl group having 1 to 6carbon atoms, such as a dimethylaminocarbonyl group, adiethylaminocarbonyl group, a dipropylaminocarbonyl group, adiisopropylaminocarbonyl group, a dibutylaminocarbonyl group, adipentylaminocarbonyl group, a dihexylaminocarbonyl group, etc.; and anasymmeteric dialkylaminocarbonyl group disubstituted by different alkylgroups each having 1 to 6 carbon atoms, such as anethylmethylaminocarbonyl group, a methylpropylaminocarbonyl group, anethylpropylaminocarbonyl group, a butylmethylaminocarbonyl group, abutylethylaminocarbonyl group, a butylpropylaminocarbonyl group, etc.

The term "N-lower alkyl-hydroxyaminocarbonyl group" means ahydroxyaminocarbonyl group ##STR9## in which the hydrogen atom bonded tothe nitrogen atom is substituted by the above-described "lower alkylgroup". Practical examples thereof are an N-methylhydroxyaminocarbonylgroup, an N-ethylhydroxyaminocarbonyl group, anN-propylhydroxyaminocarbonyl group, an N-isopropylhydroxyaminocarbonylgroup, an N-butylhydroxyaminocarbonyl group, anN-isobutylhydroxyaminocarbonyl group, an N-pentylhydroxycarbonyl group,an N-isopentylhydroxyaminocarbonyl group, an N-hexylhydroxyaminocarbonylgroup, etc.

The terms "carboxy lower alkyl group", "lower alkoxycarbonyl lower alkylgroup", and "lower alkoxyphenyl lower alkoxycarbonyl lower alkyl group"mean the aforesaid "lower alkyl groups" an optional hydrogen atom ofeach of which is substituted by the "carboxy group", "loweralkoxycarbonyl group" or "lower alkoxyphenyl lower alkoxycarbonylgroup", respectively. In addition, the "lower alkoxyphenyl loweralkoxycarbonyl group" means the aforesaid "lower alkoxycarbonyl group "an optional hydrogen atom of which is substituted by a phenyl grouphaving the above-described "lower alkoxy group" at the ortho-, meta- orpara-position.

Preferred examples of the 5- or 6-membered heterocyclic ring having 1 to3 hetero atoms selected from an oxygen atom, a sulfur atom, and anitrogen atom shown by Het are a 1,3-thiazole ring ##STR10## a4,5-dihydro-1,3-thiazole ring ##STR11## an isothiazole ring ##STR12## a1,3,4-thiadiazole ring ##STR13## a 1,2,4-thiadiazole ring ##STR14## a1,3-oxazole ring ##STR15## a 4,5-dihydroxazole ring ##STR16## anisoxazole ring ##STR17## a 1,3,4-oxadiazole ring ##STR18## an imidazolering ##STR19## a pyrazole ring ##STR20## a 1H-1,2,3-triazole ring##STR21## a 1H-1,2,4-triazole ring ##STR22## a 2H-pyran ring ##STR23## a4H-pyran ring ##STR24## a pyrimidine ring ##STR25## etc. Also, practicalexamples of the condensates of these heterocyclic rings and a benzenering are benzotiazole ring ##STR26## a benzimidazole ring ##STR27## etc.

The heterocyclic ring has 1 to 3 substituents as R³, R⁴, and R⁵ and alsowhen the heterocyclic ring is condensed with a benzene ring, thesubstituents as R³, R⁴, and R⁵ mean those bonded to the heterocyclicring moiety. Therefore, according to the nature of the heterocyclicring, there is a case that the substituents, R³, R⁴, and R⁵ cannot bondto the carbon atom(s) of the ring and this case means that R³, R⁴ and/orR⁵ is absence.

Practical examples of the substituents R³, R⁴, and R⁵ of the hydrogenatom(s) of the heterocyclic ring are a lower alkyl group, a hydroxy-,mercapto-, carboxy-or lower alkoxycarbonyl-substituted lower alkylenegroup shown by the formula -A¹ -R⁶ ; a hydroxy group; a mercapto group;a lower alkoxy group; a lower alkylthio group; a carboxy-, loweralkoxycarbonyl-, mono or di lower alkylaminocarbonyl-,hydroxyaminocarbonyl-, or N-lower alkylhydroxyaminocarbonyl-substitutedlower alkoxy or lower alkylthio group shown by the formula --Y¹ --A²--R⁷ ; an oxo group; a thioxo group; an amino group; a carboxy- or loweralkoxycarbonyl-substituted lower alkylamino group shown by formula--NH--R⁸ ; a carboxy lower alkanoylamino group, a lower alkoxycarbonyllower alkanoylamino group, a lower alkoxyphenyl lower alkoxycarbonyllower alkanoylamino group, an oxaloamino group, or a loweralkoxyoxalylamino group each shown by the formula --NH--CO--R⁹ ; acarboxy group; a lower alkoxycarbonyl group shown by formula --C--R¹⁰.

In addition, the "lower alkanoyl group" of the above-described "carboxylower alkanoylamino group", "lower alkoxycarbonyl lower alkanoylaminogroup", and "lower alkoxyphenyl lower alkoxycarbonyl lower alkanoylaminogroup" means a straight chain or branched alkylcarbonyl group having 2to 6 carbon atoms, such as an acetyl group, a propionyl group, a butyrylgroup, an isobutyryl group, a valeryl group, an isovaleryl group, apivaloyl group, a hexanoyl group, etc.

The compound of this invention shown by the abovedescribed generalformula (I) includes optical isomers based on the existence of anasymmetric carbon; tautomers based on the kind of the heterocyclic ringor the existence of an oxo group, a hydroxy group, a thioxo group or amercapto group; and cis, trans geometrical isomers based on twodifferent substituents bonded to the saturated or partially saturatedheterocyclic ring. The compound of this invention includes thoseisolated from these isomers and a mixture of them.

Some of the compounds of this invention form salts thereof and thecompounds of this invention also include the salts of the compoundsshown by the general formula (I). Examples of such salts are the saltswith an inorganic base such as sodium, potassium, etc.; the salts withan organic base such ethylamine, propylamine, diethylamine,triethylamine, morpholine, piperidine, N-ethylpiperidine,diethanolamine, cyclohexylamine, etc.; the salts with a basic amino acidsuch as lysine, ornithine, etc.; the ammonium salts; the salts with amineral acid such as hydrochloric acid, sulfuric acid, phosphoric acid,hydrobromic acid, etc.; the salts with an organic acid such as aceticacid, oxalic acid, succinic acid, citric acid, maleic acid, fumaricacid, tartaric acid, methansulfonic acid, etc.; and the salts with anacidic amino acid such as glutamic acid, aspartic acid, etc.

The compounds of this invention shown by general formula (I) can beprepared by various processes. Typical production process of thecompounds are illustrated below. ##STR28##

In the above formulae, R¹, R², A, Y, Het , R³, R⁴, R⁵, Y¹, A², R⁷, andR⁹ have the same significance as defined above and other symbols havethe following meanings:

X: A halogen atom.

M: A hydrogen atom or an alkali metal atom.

Y² : An oxygen atom or a sulfur atom.

R¹¹ : A hydrogen atom or a lower alkyl group.

R¹² : A lower alkyl group or a hydroxy group.

Y³ : a single bond, an oxygen atom, a sulfur atom, or an imino group(--NH--).

R¹³ : A lower alkyl group.

A³ : A single bond, a lower alkylene group or, when Y³ is an iminogroup; a carbonyl group or a carbonyl lower alkylene group.

A⁴ : A single bond or a lower alkylene group having 1 to 4 carbon atoms.

R^(3'), R^(4'), and R^(5') : Same or different, a hydrogen atom, a loweralkyl group, a group shown by the formula --A¹ --R^(6') (wherein, A¹ isthe same as defined above and R^(6') represents a hydroxy group, acarboxy group, or a lower alkoxycarbonyl group), a hydroxy group, alower alkoxy group, a lower alkylthio group, a group shown by theformula --Y¹ --A² --R^(7') (wherein, Y¹ and A² are the same as definedabove and R^(7') represents a lower alkoxycarbonyl group, ahydroxyaminocarbonyl group, a mono- or di-lower alkylaminocarbonylgroup, or an N-lower alkylhydroxyaminocarbonyl group), an oxo group(═O), an amino group, a group shown by the formula --NH--R^(8')(wherein, R^(8') represents a lower alkoxycarbonyl group), a group shownby the formula --NH--CO--R^(9') (wherein, R^(9') represents a loweralkoxycarbonyl lower alkyl group, a lower alkoxyphenyl loweralkoxycarbonyl lower alkyl group, or a lower alkoxycarbonyl group), acarboxy group, or a group shown by the formula --CO--R¹⁰ (wherein, R¹⁰is the same as defined above).

R^(3"), R^(4"), and R^(5") : Same or different, a hydrogen atom, a loweralkyl group, a group shown by the formula --A¹ --R^(6") (wherein, A¹ isthe same as defined above and R^(6") represents a hydroxy group, acarboxy group, or a lower alkoxycarbonyl group), a hydroxy group, alower alkoxy group, a lower alkylthio group, a group shown by theformula --Y¹ --A² --R⁷ (wherein, Y¹, A², and R⁷ are same as definedabove), an oxo group (═O), an amino group, a group shown by formula--NH--R⁸ (wherein, R⁸ is the same as defined above), a group shown bythe formula --NH--CO--R⁹ (wherein, R⁹ is same as defined above), acarboxy group, or a group shown by the formula --CO--R¹⁰ (wherein, R¹⁰is the same as defined above).

In addition, a halogen atom includes a iodine atom, a bromine atom, achlorine atom, etc., and an alkali metal atom includes sodium,potassium, etc.

Process A:

The compound of this invention shown by the general formula (I) whereinY is an oxygen atom or a sulfur atom is produced by reacting a halogencompound shown by the general formula (II) and a hydroxy compound ormercapto compound shown by the general formula (III), or an alkali metalsubstitution product thereof.

The reaction is performed using the compound of the formula (II) and thecompound of the formula at an almost equimolar amount or at a slightlyexcessive amount in one of them in an organic solvent such asdimethylformamide, dimethylsulfoxide, methanol, ethanol, propanol,acetone, methyl ethyl ketone, tetrahydrofuran, chloroform, dioxane,etc., water, or a mixed solvent thereof.

When the hydroxy- or mercapto-substituted heterocyclic compound is usedas the compound of the formula (III), the reaction is usually performedin the presence or a base and suitable examples of such a base arepotassium carbonate, Triton B, potassium hydroxide, sodium hydroxide,sodium hydride, etc.

There is no particular restriction on the reaction temperature but thereaction is usually performed at room temperature of under heating.

Process B:

The compound of the formula (Ib) which is the compound of this inventionshown by the general formula (I) wherein Y is a carbonylimino group(--CONH--) is produced by reacting a carboxylic acid shown by thegeneral formula (IV) or the reactive derivative thereof and an aminocompound shown by the general formula (V).

As the reactive derivatives of the compound of the formula (IV), thereare acid halide such as acid chloride, acid bromide, etc.; acid azides;active esters prepared with N-hydroxybenzotriazole orN-hydroxysuccinimide; symmetric acid anhydrides; mixed acid anhydridesprepared with alkyl chlorocarbonate or p-toluenesulfonyl chloride; etc.

When the compound of formula (IV) is used as a free carboxylic acid, itadvantageous to perform the reaction in the presence of a condensingagent such as dicyclohexylcarbodiimide, 1,1'-carbonyldiimidazole, etc.

The reaction is performed using the compound of the formula (IV) or thereactive derivative thereof and the compound of the formula (V) at analmost equimolar amount or at a slightly excessive amount in one of themin an organic solvent inactive to the reaction, such as pyridine,tetrahydrofuran, dioxane, ether, benzene, toluene, xylene, methylenechloride, dichloroethane, chloroform, dimethylformamide, ethyl acetate,acetonitrile, etc.

According to the kind of the reactive derivative, it is sometimesadvantageous for smoothly performing the reaction to add a base such astriethylamine, pyridine, picoline, lutidine, N,N-dimethylaniline,potassium carbonate, sodium hydroxide, etc. Pyridine can be also used asthe solvent.

The reaction temperature depends upon the kind of the reactivederivative and there is not particular restriction.

Process C:

The compound of the formula (Ic), which is the compound of thisinvention shown by the general formula (I) wherein Y is an iminocarbonylgroup (--NHCO--) is produced by reacting an amine shown by the generalformula (VI) and a carboxylic acid shown by the general formula (VII).

The reaction conditions, etc., are the same as those in Process B.

Process D:

The compound of the general formula (Id) wherein the heterocyclic ringis substituted by a lower alkoxy group, a lower alkylthio group, a loweralkoxycarbonyl lower alkoxy group, a lower alkoxycarbonyl loweralkylthio group, a carboxy lower alkoxy group, a carboxy lower alkylthiogroup, a lower alkoxycarbonyl lower alkoxy group, or a loweralkoxycarbonyl lower alkylthio group can be produced by reacting thecompound of this invention shown by the general formula (VIII) whereinthe heterocyclic ring is substituted by a hydroxy group or a mercaptogroup, or the alkali metal substitution product of the compound and ahalogen compound of the formula (IX).

The reaction is performed almost the same as Process A.

When the compound of the formula (VIII) wherein the heterocyclic ringhas plural of group shown by the formula --Y¹ --M is used as the rawmaterial, it is possible to prepare the compound wherein a group shownby the formula --A² --R⁷ is introduced to all of the group of --Y¹ --Mas the desired product.

Process E:

The compound of this invention wherein the heterocyclic ring issubstituted by a carboxy lower alkanoylamino group, a loweralkoxycarbonyl lower alkanoylamino group, a lower alkoxyphenyl loweralkoxycarbonyl lower alkanoylamino group, an oxaloamino group or a loweralkoxyoxalylamino group can be produced by reacting a compound shown bythe general formula (Ie) wherein the heterocyclic ring is substituted byan amino group and a carboxylic acid shown by the general formula (X) orthe reactive derivative thereof.

The reaction conditions, etc., are almost the same as those in ProcessesB and C.

When the compound wherein the heterocyclic ring has plural amino groupsis used as the raw material, the compound wherein all the amino groupsare reacted can be obtained.

Process F:

The compound of this invention wherein the heterocyclic ring issubstituted by a mono- or di-lower alkylaminocarbonyl lower alkoxygroup, a mono- or di-lower alkylaminocarbonyl lower alkylthio group, an(N-lower alkyl)hydroxyaminocarbonyl lower alkoxy group, or an (N-loweralkyl)hydroxyaminocarbonyl lower alkylthio group is produced by reactinga carboxylic acid shown by the general formula (Ig) or the reactivederivative thereof and an amine shown by the general formula (XI).

The reaction is performed in the same method as the case of Processes B,C and E.

When the compound wherein the heterocyclic ring having plural carboxygroups is used as the raw material, the compound wherein the carboxygroups are wholly or selectively reacted can be obtained as the desiredproduct.

Process G:

The free carboxylic acid compound shown by the general formula (Ij) canbe easily produced by the hydrolysis of a corresponding ester compoundshown by the general formula (Ii).

In the reaction, an ordinary process of performing hydrolysis in thepresence of a base such as sodium carbonate, sodium hydroxide, etc., oran acid such as trifluoroacetic acid, hydrochloric acid, etc., can beapplied.

When the compound wherein the heterocyclic ring has plural esters isused as the raw material, the compound wherein all the esters arehydrolyzed may be induced.

Process H:

The compound of this invention shown by the general formula (Ik) havingno free mercapto group, carboxy group and reactive hydroxy group isproduced by reacting a dihydroxybenzene derivative shown by the generalformula (XII) or the alkali metal substitution product thereof and ahalogen compound shown by the general formula (XIII).

The reaction is performed in the same method as the case of Processes Aand D wherein, in particular, the compound in which Y¹ or Y² is anoxygen atom is used.

Process I:

The compound of this invention wherein A is a 2-hydroxy lower alkylenegroup can be produced by reacting an epoxy compound shown by the generalformula (XIV) and a hydroxy or mercapto compound (having no othermercapto group) or the alkali metal substitution product thereof.

The reaction is substantially the same as Processes A, D, and H. Thatis, the reaction is performed using the compound of formula (XIV) andthe compound of formula (XV) at an almost equimolar amount or anexcessive amount in one of them in an organic solvent inactive to thereaction, such as dimethylformamide, dimethylsulfoxide, methanol,ethanol, propanol, acetone, ethyl methyl ketone, tetrahydrofuran,chloroform, dioxane, etc. When a free hydroxy compound or mercaptocompound is used as the compound of formula (XV), the reaction isperformed in the presence of a base such as potassium carbonate, TritonB, potassium hydroxide, sodium hydroxide, sodium hydride, etc., under,preferably, water-free conditions.

Process J:

Contrary to the case of Process G, the ester compound shown by thegeneral formula (Ii) is synthesized by reacting a carboxylic acid shownby the general formula (Ij) or the reactive derivative thereof and alower alcohol or a reactive derivative of an alcohol component such as alower alkyl halide, etc., shown by general formula (XVI).

The reaction can be easily accomplished by an ordinary process.

The compounds of this invention produced by the various processesdescribed above can be isolated and purified by the application of anoperation usually used in the field of the art, such as extraction,recrystallization, column chromatography, etc.

The compounds of this invention shown by general formula (I) stronglyantagonize to the actions of SRS-A as described hereinbefore and henceare useful for the prophylaxis and treatment of various allergicdiseases (e.g., bronchial asthma, allergic rhinitis, urticaria, etc.)caused by SRS-A and also ischemic heart desieases and ischemic braindeseases inflamations, etc., caused by SRS-A.

Also, the compounds of this invention include, besides those having theactivity antagonizing the actions of SRS-A, the compounds having theaction of inhibiting the production and release of SRS-A and abronchodilator action is addition to the aforesaid activity.Furthermore, the compounds of this invention are also useful as antiulcer agent.

Inhibition of SRS-A- and LTD⁴ -induced contraction of guinea pig ileumand trachea

Method: Male Hartley guinea-pigs, weighing 500 to 700 g were killed by ablow on the head. The ileum and tracheal strips prepared according tothe method of Constantine (1965) were suspended with 1.0 g tension in anorgan bath containing 10 ml of Tyrode's solution equilibrated with amixture of 95% O₂ and 5% CO₂ at 37° C. The tissues were equilibrated for60 min.; during this period the Tyrode's solution was replaced every 15min. and the loading tension was adjusted to 1.0 g. The developedtension of the tissues was measured isometrically with a strain gaugetransducer, and recorded on a Recticorder. Both the contractile responseof the ileum to submaximal concentration of SRS-A (derived fromguinea-pig lung) and the tracheal response to 10⁻⁸ M LTD₄ were measuredin the absence and then the presence of various concentrations of testcompounds. The incubation time of the compounds was 20 min.

                  TABLE 1                                                         ______________________________________                                                  Anti-SRS-A              Anti-SRS-A                                            GP ileum                GP ileum                                    Example No.                                                                             IC50 (M)   Example No.  IC50 (M)                                    ______________________________________                                         2        1.8 × 10.sup.-7                                                                    36           1.4 × 10.sup.-7                        7        1.1 × 10.sup.-7                                                                    37           5.2 × 10.sup.-8                       21        6.0 × 10.sup.-8                                                                    38           3.8 × 10.sup.-8                       23        1.5 × 10.sup.-7                                                                    41           6.4 × 10.sup.-8                       24        1.9 × 10.sup.-7                                                                    42           1.3 × 10.sup.-7                       26        1.2 × 10.sup.-7                                                                    44           1.3 × 10.sup.-7                       27        1.9 × 10.sup.-7                                                                    46           1.1 × 10.sup.-7                       33        9.1 × 10.sup.-8                                                                    51           1.6 × 10.sup.-7                       ______________________________________                                    

                  TABLE 2                                                         ______________________________________                                                       Anti-LTD.sub.4                                                                GP trachea                                                     Example No.    IC50 (M)                                                       ______________________________________                                        21             1.3 × 10.sup.-7                                          38             2.3 × 10.sup.-7                                          51             4.2 × 10.sup.-7                                          ______________________________________                                    

Inhibition of SRS-A-mediated anaphylactic asthma in consciousguinea-pigs

Method: Male Hartley guinea-pigs, weighing 370 to 410 g were passivelysensitized by intravenously injecting 1 ml/kg of rabbit anti-bovineserum albumin serum (PHA titer: 20480). Twenty-four hours after thesensitization, indomethacine (2 mg/kg), mepyramine (2 mg/kg) andpropranolol (0.3 mg/kg) were injected into the saphenous vein 20, 5 and5 min., respectively, prior to the antigen challenge. Then, animals wereplaced in an 11 liter chamber connected to a glass nebulizer, and 1%solution of bovin serum albumin was sprayed into the chamber for 30seconds. The animals were exposed to the antigen aerosol for 2 min. andobserved for 15 min. after challenge. The time from the start ofinhalation to the onset of cough and the mortality were recorded. Testcompounds were orally administered 30 min. before antigen challenge.

Result: Compound of Example 21 at 3 mg/kg p.o. tended to inhibit theSRS-A-mediated anaphylactic asthma in conscious guinea-pigs, but thiseffect was not significant (Table 3). At the doses of 10 mg/kg p.o. orhigher, compound of Example 21 significantly inhibited theSRS-A-mediated anaphylactic asthma.

                  TABLE 3                                                         ______________________________________                                        Effect of Compound of Example 21 on SRS-A-mediated                            anaphylactic astham in conscious guinea-pigs.sup.(a)                                                       Time to                                                    Dose               onset of                                         Compound.sup.(b)                                                                        (mg/kg p.o.)                                                                             N       cough (sec)                                                                            Mortality                               ______________________________________                                        Control   --         8       293 ± 22                                                                            6/8                                     Compound.sup.(c)                                                                        3          8       377 ± 51                                                                            5/8                                     Control   --         8       281 ± 19                                                                            7/8                                     Compound.sup.(c)                                                                        10         8       397 ± 42*                                                                            2/8*                                   Control   --         8       281 ± 11                                                                            7/8                                     Compound.sup.(c)                                                                        30         8       457 ± 42**                                                                           2/8*                                   ______________________________________                                         .sup.(a) Animals were pretreated with mepyramine (2 mg/kg                     i.v.),propranolol (0.3 mg/kg i.v.) and indomethacine (2 mg/kg i.v.) 5, 5      and 20 min., respectively, prior to antigen challenge.                        .sup.(b) Test compound was orally administered 30 min. before antigen         challenge.                                                                    .sup.(c) Compound of Example 21.                                              *p <0.05,                                                                     **p <0.01: Significantly differed from the value of the control group.   

Toxicity

The minimum fatal dose in the case of orally administering the compoundof Example 21 to mice and rats was more than 1000 mg/kg in each case.

The compounds of this invention shown by the general formula (I) or thesalts thereof can be orally or parenterally administered as they are oras medical compositions composed of these compounds and pharmaceuticallypermissible carriers or excipients (e.g., tablets, capsules, powders,granules, pills, ointments, syrups, injections, inhalants,suppositories, etc.). The dose is depends upon the patients,administrating routes, symptoms, etc., but is usually 0.1 to 500 mg,preferably 1 to 200 mg per adult per day and is orally or parenterallyadministered 2 or 3 times per day.

Then, the invention will be explained by the following example indetail.

In addition, the production examples of the raw material compounds usedin these examples are shown in the following reference examples, whereinnPr means a n-propyl group.

REFERENCE EXAMPLE 1 ##STR29##

After stirring a mixture of 60 g of 2,5-dimercapto-1,3,4-thiadiazole, 25g of potassium hydroxide, and 750 ml of ethanol for one hour at 70° C.,68 g of ethyl α-bromoacetate was added to the mixture and then theresultant mixture was refluxed for 2 hours. After cooling the reactionmixture, insoluble matters were filtered off and the filtrate thusformed was concentrated under reduced pressure. To the residue thusformed was added 600 ml of 10% sodium hydroxide. The mixture was stirredfor one hour at 80° C. After cooling, the reaction mixture was acidifiedby the addition of concentrated hydrochloric acid (below pH 1) andcrystals thus formed were collected by filtration, washed with water,and recrystallized from acetone to provide 60 g of[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]acetic acid.

Melting point: 170° C.

REFERENCE EXAMPLE 2 ##STR30##

To a mixture of 3 g of 2,5-dimercapto-1,3,4-thiadiazole, 2.76 g ofanhydrous potassium carbonate, and 10 ml of N,N-dimethylformamide wasadded 1 g of ethyl 4-bromobutyrate and the mixture was stirred overnightat room temperature. After addition of diluted hydrochloric acid to thereaction mixture, the product was extracted with ethyl acetate. Theextract was washed with water, dried over anhydrous magnesium sulfate,and concentrated under reduced pressure. The residue thus obtained wasapplied to silica gel chromatography (using 200 ml of silica gel) andeluted with a mixture of toluene and ethyl acetate (9:1) to provide 0.95g of ethyl 4-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]butyrate.

Melting point: 107° to 108° C.

REFERENCE EXAMPLE 3 ##STR31##

A mixture of 1.42 g of 2,4-dihydroxy-3-propylacetophenone, 2 g of ethyl4-bromobutyrate, 1.5 g of potassium carbonate, and 10 ml ofN,N-dimethylformamide was stirred overnight at room temperature. Afteraddition of 100 ml of water to the reaction mixture, the product wasextracted with 30 ml of toluene. The extract was washed with water,dried over anhydrous magnesium sulfate. The solvent was distilled off.The residue thus formed was applied to silica gel column chromatographyand eluted with toluene to provide 1.5 g of ethyl4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyrate as an oily product. In asolution of 2 g of potassium hydroxide dissolved in 40 ml 80% ofmethanol was dissolved 1.3 g of the oily product and the solution wasallowed to stand for one hour. To the reaction mixture was added 20 mlof water and methanol was distilled off under reduced pressure. Theaqueous solution thus obtained was acidified by 5% hydrochloric acid andextracted by ethyl acetate. The extract thus formed was washed withwater, dried over anhydrous magnesium sulfate. The solvent was distilledoff to provide 1.1 g of 4-(4-acetyl-3-hydroxy-2-propylphenoxy)-butyricacid.

Melting point: 138° to 139° C.

REFERENCE EXAMPLE 4 ##STR32##

In a mixture of 9.66 g of sodium hydroxide, 14.6 ml of water, and 122 ofmethanol was dissolved 36.3 g of 2,5-dimercapto-1,3,4-thiadiazole. Aftercooling the mixture, a solution of 24.1 ml of ethyl bromoacetate and 24ml of methanol was added to the mixture below 10° C. The resultantmixture was stirred for 3 hours at room temperature and cooled below 10°C. 43.5 ml of water and 400 ml of 50% methanol were successively addedto the reaction mixture, whereby crystals precipitated, and the mixturewas allowed to stand overnight at 4° C. The crystals were collected byfiltration, washed successively with water and then 50% methanol, anddried to provide 42.5 g of ethyl[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]acetate.

Melting point: 67° to 68° C.

REFERENCE EXAMPLE 5 ##STR33##

To a mixture of 10 g of 2,5-dimercapto-1,3,4-thiadiazole and 100 ml ofmethanol were added 2.6 g of sodium hydroxide and 5 ml of water. To themixture was gradually added 9 g of ethyl 5-bromovalerate.

The resultant mixture was stirred for one hour at room temperature. Thereaction mixture thus obtained was concentrated under reduced pressure.After addition of 100 ml of water to the residue, the product wasextracted with ethyl acetate. The extract thus formed was washed withwater, dried over anhydrous magnesium sulfate, and concentrated underreduced pressure. The residue was applied to silica gel columnchromatography and eluted with a mixture of toluene and ethyl acetate(9:1) to provide 10 g of ethyl5-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]valerate.

Melting point: 53° C.

REFERENCE EXAMPLE 6 ##STR34##

To a mixture of 7.6 g of 2,5-dimercapto-1,3,4-thiadiazole, 1.5 ml ofwater, 15 ml of methanol, and 2.0 g of sodium hydroxide was added 7.4 gof ethyl 6-bromohexanoate and the mixture was stirred for 2 hours atroom temperature. After being acidified the reaction mixture thusobtained with diluted hydrochloric acid, 150 ml of water was addedthereto. The mixture was extracted with toluene and the extract thusformed was washed with water, dried over anhydrous magnesium sulfate,and concentrated under reduced pressure. The residue thus formed wasrecrystallized from a mixture of toluene and n-hexane to provide ethyl6-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]hexanoate.

Melting point: 79° to 80° C.

REFERENCE EXAMPLE 7 ##STR35##

By following the same procedure as Reference Example 6 using 6.9 g of2,5-dimercapto-1,3,4-thiadiazole and 5.8 g of ethyl 4-chlorovalerate asthe starting materials, 1.5 g of ethyl4-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]valerate was obtained as anoily product.

Nuclear magnetic resonance spectra (CDCl₃, TMS internal standard, ppm)

1.25(t, 3H), 1.45(d, 3H), 2.08(t, 2H), 2.52(t, 2H), 3.70(q, 1H), 4.15(q,2H)

REFERENCE EXAMPLE 8 ##STR36##

By following the same procedure as Reference Example 6 using 7.5 g of2,5-dimercapto-1,3,4-thiadiazole and 5.8 g of ethyl 2-bromopropionate asthe starting materials, 6.1 g of ethyl2-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]propionate was obtained as anoily product.

Nuclear magnetic resonance spectra (CDCl₃, TMS internal standard, ppm)

1.28(t, 3H), 1.64(d, 3H), 4.0-4.80(m, 3H)

REFERENCE EXAMPLE 9 ##STR37##

To a mixture of 1.5 g of 2,5-dimercapto-1,3,4-thiadiazole, 1.3 g ofanhydrous potassium carbonate, and 20 ml of N,N-dimethylformamide wasadded 1.6 g of 3-bromopropionic acid, whereby the red color of thereaction mixture began to gradually fade and the reaction mixture becameyellow. Then, the reaction mixture was poured into 100 ml of ice waterand extracted with 30 ml of ethyl acetate three times. The extract thusobtained was washed with water and extracted with 20 ml of an aqueoussolution of 5% sodium hydrogen carbonate two times. The extract waswashed with ethyl acetate, acidified with diluted hydrochloric acid, andextracted with 30 ml of ethyl acetate three times and the extract thusobtained was washed with water, dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to provide 0.76 g of3-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]propionic acid.

Melting point: 105° to 108° C.

REFERENCE EXAMPLE 10 ##STR38##

A mixture of 3 g of 2,4-dihydroxy-3-propylacetophenone, 2.5 g of ethylbromoacetate, 2.3 g of anhydrous potassium carbonate, and 30 ml ofmethyl ethyl ketone was refluxed for 5 hours. Then, the solvent wasremoved under reduced pressure and after addition of 50 ml of toluene,the mixture was washed with water, a diluted aqueous solution of sodiumhydroxide, and water successively, dried over anhydrous magnesiumsulfate, and concentrated under reduced pressure. The residue thusformed was recrystallized from a mixture of toluene and n-hexane toprovide 2.8 g of ethyl (4-acetyl-3-hydroxy-2-propylphenoxy)acetate(melting point: 66° to 66.5° C.).

A mixture of the product thus obtained, 20 ml of methanol, and 8 ml of a2N aqueous solution of sodium hydroxide was stirred for 2 hours at 50°C. Then, the reaction mixture thus obtained was concentrated underreduced pressure, added 30 ml of water, and washed with toluene. Theaqueous layer was acidified with diluted hydrochloric acid and extractedwith ethyl acetate. The extract thus formed was washed with water, driedover anhydrous magnesium sulfate, and concentrated under reducedpressure. The residue thus formed was recrystallized from isopropanol toprovide 2.3 g of (4-acetyl-3-hydroxy-2-porpylphenoxy)acetic acid.

Melting point: 140° to 141° C.

REFERENCE EXAMPLE 11 ##STR39##

A mixture of 1 g of 2,4-dihydroxy-3-propylacetophenone, 1.1 g of1-bromo-2-chloroethane, 0.75 g of anhydrous potassium carbonate, and0.05 g of tetra-n-butylammonium bromide was refluxed for 3 hours withvigorous stirring. After cooling, 30 ml of toluene was added to thereaction mixture and the mixture was washed with a diluted aqueoussolution of sodium hydroxide, washed with water, dried over anhydrousmagnesium sulfate, and concentrated under reduced pressure. The residuethus formed was recrystallized from isopropanol to provide 0.46 g of4-(2-chloroethoxy)-2-hydroxy-3-propylacetophenone.

Melting point: 73° to 74° C.

Elemental analysis for C₁₃ H₁₇ O₃ Cl:

    ______________________________________                                                 C          H       Cl                                                ______________________________________                                        Calculated:                                                                              60.82%       6.67%   13.81%                                        Found:     60.67%       6.72%   13.76%                                        ______________________________________                                    

REFERENCE EXAMPLE 12 ##STR40##

By following the same procedure as Reference Example 11 using 1 g of2,4-dihydroxy-3-propylacetophenone and 4.5 g of 1,4-dibromobutane asstarting materials followed by purification by silica gel columnchromatography (Eluant: toluene), 1.3 g of4-(4-bromobutoxy)-2-hydroxy-3-propylacetophenone was obtained as an oilyproduct.

Nuclear magnetic resonance spectra (CDCl₃, TMS internal standard, ppm)

0.95(t, 3H), 1.10-1.80(m, 2H), 1.80-2.20(m, 4H), 2,58(s, 3H), 2,64(t,2H), 3,52(t, 2H), 4,08(t, 2H), 6.42(d, 1H), 7.58(d, 1H), 12.7(s, 1H).

REFERENCE EXAMPLE 13 ##STR41##

By following the same procedure as Reference Example 12 using 1 g of2,4-dihydroxy-3-propylacetophenone and 4.7 g of 1,5-dibromopentane asthe raw materials, 1.3 g of4-(5-bromopentyloxy)-2-hydroxy-3-propylacetophenone was obtained as anoily product.

Nuclear magnetic resonance spectra (CDCl₃, TMS internal standard, ppm)

0.94(t, 3H), 1.30-2.10(m, 8H), 2.56(s, 3H), 2.64(t, 2H), 3,46(t, 2H),4,40(t, 2H), 6,42(d, 1H), 7.58(d, 1H), 12.72(s, 1H).

REFERENCE EXAMPLE 14 ##STR42##

A mixture of 3 g of ethyl[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]acetate, 9 g of1,3-dibromopropane, 2.02 g of anhydrous potassium carbonate, 0.01 g oftetra-n-butylammonium bromide, and 20 ml of methyl ethyl ketone wasvigorously stirred for 3 hour at 60° C. Toluene was added to thereaction mixture and the resultant mixture was washed with water, driedover anhydrous magnesium sulfate, and concentrated under reducedpressure. The residue thus formed was applied to silica gel columnchromatography and eluted with a mixture of toluene and ethyl acetate(9:1) to provide 1.35 g of ethyl[[5-(3-bromopropyl)thio-1,3,4-thiadiazol-2-yl]thio]acetate.

Melting point: 118° to 120° C.

EXAMPLE 1 ##STR43##

To a mixture of 600 mg of 2,5-dimercapto-1,3,4-thiadiazole, 560 mg ofanhydrous potassium carbonate, and 10 ml of N,N-dimethylformamide wasadded 250 mg of 4-(2,3-epoxy)propoxy-2-hydroxy-3-propylacetophenone andthe resultant mixture was stirred overnight at room temperature. To thereaction mixture thus obtained was added diluted hydrochloric acid andthe product was extracted with toluene. The extract thus obtained waswashed with water, dried over anhydrous magnesium sulfate, andconcentrated under reduced pressure. The residue was applied to silicagel column chromatography and eluted with a mixture of toluene and ethylacetate (4:1) to provide 260 mg of2-hydroxy-4-[2-hydroxy-3-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]-propoxy]-3-propylacetophenoneas an oily product.

Nuclear magnetic resonance spectra (CDCl₃, TMS internal standard, ppm)

0.92(t, 3H), 1.2-1.8(m, 2H), 2.56(s, 3H), 2,63(t, 2H), 3,48(dd, 2H),4.0-4.2(m, 2H), 4.2-4.6(m, lH), 6,42(dd, 1H), 7.61(d, 1H), 12.7(s, 1H).

EXAMPLE 2 ##STR44##

A mixture of 2 g of 4-(3-bromopropoxy)-2-hydroxy-3-propylacetophenone,1.6 g of 2-amino-5-mercapto-1,3,4-thiadiazole, 1.6 g of potassiumcarbonate, and 20 ml of N,N-dimethylformamide was stirred for one hourat 20° to 30° C. and after addition of 100 ml of water to the reactionmixture thus obtained, the product was extracted with ethyl acetate. Theextract was washed with water, dried over anhydrous magnesium sulfate,and then the solvent was distilled off. The residue thus formed wasapplied to silica gel column chromatography and eluted with toluene toprovide 2.3 g of4-[3-[(5-amino-1,3,4-thiadiazol-2-yl)thio]propoxy]-2-hydroxy-3-propylacetophenone.

Melting point: 144° to 145° C.

Elemental analysis for C₁₆ H₂₁ N₃ O₃ S₂ :

    ______________________________________                                                 C     H          N       S                                           ______________________________________                                        Calculated:                                                                              52.29%  5.76%      11.43%                                                                              17.45%                                    Found:     52.09%  5.71%      11.58%                                                                              17.61%                                    ______________________________________                                    

EXAMPLES 3 to 13

By following the same procedure as Example 2 following compounds wereobtained.

EXAMPLE 3

Starting compound: ##STR45##

Desired compound:2-Hydroxy-3-propyl-4-[3-[(2-thiazolin-2-yl)thio]propoxy]acetophenone##STR46##

Physicochemical properties:

(1) Oily product

(ii) Nuclear magnetic resonance spectra (TMS, CDCl₃, ppm)

0.92(3H, t, J=6Hz), 1.2-1.8(2H), 2.0-2.8(4H), 2,55(3H, s), 3.2-3.5(4H),4.0-4.3(4H), 6.38 (1H, d, J=9Hz), 7.56(1H, d, J=9Hz), 12.7(1H).

EXAMPLE 4

Starting compound: ##STR47##

Desired compound:2-Hydroxy-3-propyl-4-[3-[(1H-1,2,3-triazol-4-yl)thio]propoxy]acetophenone##STR48##

Physicochemical properties:

(i) Oily product

(ii) Nuclear magnetic resonance spectra (TMS, CDCl₃, ppm)

0.8-1.1(3H), 1.2-1.8(2H), 2.0-2.8(5H), 2.55 (3H, s), 3.0-3.2(1H),3.9-4.3(2H), 4.5-4.7(1H), 6.3-6.4(1H), 7.5-7.6(2H), 12.8(1H)

EXAMPLE 5

Starting compound: ##STR49##

Desired compound:4-]3-[(5-Amino-2H-1,2,4-triazol-3-yl)thio]propoxy]-2-hdyroxy-3-propylacetophenone##STR50##

Physicochemical properties:

(i) Melting point: 171° to 172° C.

(ii) Elemental analysis for C₁₆ H₂₂ N₄ O₃ S:

    ______________________________________                                                 C          H       N                                                 ______________________________________                                        Calculated:                                                                              54.84%       6.33%   15.99%                                        Found:     55.07%       6.62%   15.77%                                        ______________________________________                                    

EXAMPLE 6

Starting compound: ##STR51##

Desired compound:2-Hydroxy-4-[3-[(6-hydroxymethyl-4-oxo-4H-pyran-3-yl)oxy]propoxyl]-3-propylacetophenone##STR52##

Physicochemical Properties:

(i) Melting point: 84° to 87° C.

(ii) Elemental analysis for C₂₀ H₂₄ O₇ :

    ______________________________________                                                       C     H                                                        ______________________________________                                        Calculated:      63.82%  6.43%                                                Found:           63.73%  6.67%                                                ______________________________________                                    

EXAMPLE 7

Starting compound: ##STR53##

Desired compound:2-Hydroxy-4-[[3-(5-mercapto-1,3,4-thiadiazol-2-yl)thio]propoxy]-3-propylacetophenone##STR54##

Physicochemical Properties:

(i) Melting point: 127° to 129° C.

(ii) Elemental analysis for C₁₆ H₂₀ N₂ O₃ S₃ :

    ______________________________________                                                  C     H         N       S                                           ______________________________________                                        Calculated: 49.97%  5.24%     7.28% 25.02%                                    Found:      50.00%  5.33%     7.19% 24.82%                                    ______________________________________                                    

EXAMPLE 8

Starting compound: ##STR55##

Desired compound: Methyl6-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-2-methylthio-4-pyrimidinecarboxylate##STR56##

Physicochemical properties:

(i) Melting point: 99° to 100° C.

(ii) Nuclear magnetic reasonace spectra (TMS, CDCl₃, ppm)

1.93 (3H, t, J=6 Hz), 1.3-1.7(2H), 2.0-2.8(4H), 2.55(3H, s), 2.58 (3H,s), 3.3-3.5(2H), 3.92 (3H, s), 4.0-4.3(2H), 6.4-7.7(3H), 12.7(1H)

EXAMPLE 9

Starting compound: ##STR57## and compound of reference example 12

Desired compound:4-[4-[(2-Amino-1,3,4-thiadiazol-5-yl)thio]butoxy]-2-hydroxy-3-propylacetophenone##STR58##

Physicochemcial properties:

(i) melting point: 107° to 108° C.

(ii) Elemental analysis for C₁₇ H₂₃ N₃ O₃ S₂ :

    ______________________________________                                                  C     H         N       S                                           ______________________________________                                        Calculated: 53.52%  6.08%     11.01%                                                                              16.81%                                    Found:      53.24%  5.89%     10.97%                                                                              16.74%                                    ______________________________________                                    

EXAMPLE 10

Starting compound: ##STR59##

Desired compound:4-[3-(2-Benzothiazolylthio)propoxy]-2-hydroxy-3-propylacetophenone##STR60##

Physicochemical properties:

(i) Oily product

(ii) Elemetal analysis for C₂₁ H₂₃ NO₃ S₂ :

    ______________________________________                                                 C          H       N                                                 ______________________________________                                        Calculated:                                                                              62.81%       5.77%   3.49%                                         Found:     62.98%       5.98%   3.36%                                         ______________________________________                                    

EXAMPLE 11

Starting compound: Compound of Reference Example 2

Desired compound: Ethyl4-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]butyratePhysicochemical properties: ##STR61##

(i) Oily product

(ii) Elemental analysis for C₂₂ H₃₀ N₂ O₅ S₃ :

    ______________________________________                                                  C     H         N       S                                           ______________________________________                                        Calculated: 52.99%  6.06%     5.62% 19.29%                                    Found:      52.99%  6.11%     5.53% 19.18%                                    ______________________________________                                    

EXAMPLE 12

Starting compound: ##STR62##

Desired compound: 4-[3-[(6-Aminobenzothiazol-2-yl)thio]propoxy]-2-hydroxy-3-propylacetophenone ##STR63##

Physicochemical properties:

(i) Oily product

(ii) Nuclear magnetic reasonacen spectra (CDCl₃, TMS, ppm)

1.95(s, 3H), 1.2-2.0(2H,), 2.53(s, 3H), 2.0-2.9(4H), 4.48(t,3H),3.4-4.0(2H, --NH₂), 4.17(t,3H), 6.2-7.8(5H), 12.70(1H)

EXAMPLE 13

Starting compound: ##STR64##

Desired compound:4-[3-(2-Benzimidazolylthio)propoxy]-2-hydroxy-3-propylacetophenone##STR65##

Physicochemcial Properties:

(i) Melting point: 143° to 146° C.

(ii) Elemental analysis for C₂₁ H₂₄ N₂ O₃ S:

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              65.60%       6.29%    7.29%                                         Found     65.46%       6.34%    7.25%                                         ______________________________________                                    

EXAMPLE 14 ##STR66##

A mixture of 21.87 g of4-(3-chloropropoxy)-2-hydroxy-3-propylacetophenone, 18.18 g of ethyl[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]acetate, obtained in referenceexample 4 12.7 g of anhydrous potassium carbonate, and 80 ml of methylethyl ketone was refluxed for 2.5 hours with vigorous stirring. Aftercooling, insoluble matters were filtered off and the filtrate wasconcentrated under reduced pressure. To the residue thus formed wereadded 200 ml of ethyl acetate and 150 ml of toluene and the mixture waswashed with a diluted aqueous solution of sodium hydroxide and water,dried over anhydrous magnesium sulfate, and then concentrated underreduced pressure. The residue thus obtained was applied to silica gelcolumn chromatography and eluted with a mixture of toluene and ethylacetate (10:1) to provide 33 g of ethyl[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetate.

Melting point: 71° to 72.5° C.

Elemental analysis for C₂₀ H₂₆ N₂ O₅ S₃ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             51.04    5.57%      5.95%  20.44%                                    Found    51.07%   5.49%      5.79%  20.17%                                    ______________________________________                                    

EXAMPLES 15 to 18

By following the same procedure as Example 14, the following compoundswere prepared.

EXAMPLE 15

Starting compound: ##STR67## and the compound of Reference Example 5

Desired compound: Ethyl5-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]valerate##STR68##

Physicochemical properties:

(i) Oily product

(ii) Nuclear magnetic resonance spectra (CDCl₃, TMS, ppm)

0.92(t, 3H), 1.24(t,3H), 1.50-2.0(m, 6H), 2.34(2H), 2.54(s, 3H), 3,28(t,2H), 3,46(t, 2H), 3.8-4.4(4H), 6.42(d, 1H), 7.58(d, 1H), 12.68(s, 1H)

EXAMPLE 16

Starting compound: Compound of Reference Example 6 and ##STR69##

Desired compound: Ethyl6-[[5-[[3-(4-acetyl3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]hexanoate##STR70##

Physicochemical properties:

(i) Oily product

(ii) Nuclear magnetic reasonance spectra (CDCl₃, ppm) 0.92(t,3H),1.24(t,3H), 1.3-2.0(8H), 2.1-2.5 (4H), 2.54(s, 3H), 3.28(t,2H),3.48(t,2H), 4.0-4.3(4H), 6.43(d,1H), 7.60(d, 1H), 12.7 (s.1H)

EXAMPLE 17

Starting compound: ##STR71## and Compound of Reference Example 8

Desired compound: Ethyl2-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]propionate##STR72##

Physicochemcical properties:

(i) Oily product

(ii) Elemental analysis for C₂₁ H₂₈ N₂ O₅ S₃ :

    ______________________________________                                                      N      S                                                        ______________________________________                                        Calculated      5.78%    19.85%                                               Found           5.85     20.05%                                               ______________________________________                                    

EXAMPLE 18

Starting compound: ##STR73## and Compound of Reference example 7

Desired compound: Ethyl4-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]valerate##STR74##

Physicochemical properties:

(i) Oily product

(ii) Nuclear magnetic reasonance spectra (CDCl₃, TMS, ppm)

0.97(t,3H), 1.26(t,3H), 1.50 (d, 3H), 1.40-1.80(2H), 2.36(t,2H),2.60(s,3H), 3.52 (t, 2H), 3.90(q,lH), 4.0-4.4(4H), 6.46(d,1H),7.63(d,1H), 12.7(s, 1H)

EXAMPLE 19 ##STR75##

By following the same procedure as Example 14 using 0.45 g of2,4-dihdyroxy-3-propylacetophenone and 0.75 g of ethyl[[5-(3-bromopropyl)thio-1,3,4-thiadiazol-2-yl]thio]acetate as the rawmaterials, 0.2 g of ethyl[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetate.The properties of the product obtained were same as those of the productobtained in Example 14.

EXAMPLE 20 ##STR76##

A mixture of 596 mg of4-(3-bromopropoxy)-2-hydroxy-3-propylacetophenone, 372.4 mg of ethyl[(5-mercapto-1,3,4-thiadiazol2-yl)thio]acetate, obtained in referenceexample 4 326 mg of anhydrous potassium carbonate, and 5 ml ofN,N-dimethylformamide was stirred for 2 hours at room temperature. Thereaction mixture thus obtained was concentrated under reduced pressureand after addition of chloroform, the mixture was washed with water,dried over anhydrous magnesium sulfate, and concentrated under reducedpressure. The residue thus formed was applied to silica gel columnchromatography and eluted with a mixture of toluene and ethyl acetate(10:1) to provide 663.3 mg of ethyl[[5-[[3-(4-acetyl-3-hydroxy-2-propoxyphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetate.The properties of the compound thus obtained were same as those of thecompound obtained in Example 14.

EXAMPLE 21 ##STR77##

A mixture of 3.1 g of 4-(3-bromopropoxy)-2-hydroxy-3-propylacetophenone,2.4 g of [(5-mercapto1,3,4-thiadiazol-2-yl)thio]acetic acid, obtained inreference example 1 3 g of potassium carbonate, and 30 ml ofN,N-dimethylformamide was stirred for 3 hours at room temperature. Afteraddition of 150 ml of water to the reaction mixture obtained, theproduct was extracted with ethyl acetate. The separated aqueous layerwas acidified with 10% hydrochloric acid, and extracted with ethylacetate. The extract was washed with water, dried over anhydrousmagnesium sulfate, and then the solvent was distilled off under reducedpressure to provide a solid material. The solid material wasrecrystallied from ethanol to provide 2.5 g of[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid.

Melting point: 129° to 130° C.

Elemental analysis for C₁₈ H₂₂ N₂ O₅ S₃ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             48.85%   5.01%      6.33%  21.74%                                    Found    48.78%   5.13%      6.29%  21.49%                                    ______________________________________                                    

EXAMPLE 22 ##STR78##

By following the same procedure as Example 21 using 100 mg of2-hydroxy-4-[[-(5-mercapto-1,3,4-thiadiazol-2-yl)thio]propoxy]-3-propylacetophenoneobtained in Example 7 and 40 mg of bromoacetic acid as the startingmaterials, 70 mg of[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]-thio]-1,3,4-thiadiazol-2-yl]thio]acetic acid was obtained. The compound thus obtained had the sameproperties as those of the compound obtained in Example 21.

EXAMPLE 23 ##STR79##

A mixture of 1.3 g of 4-(4-bromobutoxy)-2-hydroxy-3-propylacetophenone,obtained in Reference Example 12, 1.0 g of[5-mercapto-1,3,4-thiadiazol-2-yl)thio]acetic acid, 1.0 g of anhydrouspotassium carbonate, and 5 ml of N,N-dimethylformamide was stirred for 3hours at 50° C. The reaction mixture thus obtained was mixed with 30 mlof water, washed with toluene, acidified with diluted hydrochloric acid,and extracted with ethyl acetate. The extract thus formed was washedwith water, dried over anhydrous magnesium sulfate, and concentratedunder reduced pressure. The residue thus formed was recrystallized fromethyl acetate to provide 1.15 g of[[5-[[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid.

Melting point: 123° to 124.5° C.

Elemental analysis for C₁₉ H₂₄ N₂ O₅ S₃ :

    ______________________________________                                                  C     H         N       S                                           ______________________________________                                        Calculated: 49.98%  5.30%     6.14% 21.07%                                    Found:      49.76%  5.29%     6.07% 21.13%                                    ______________________________________                                    

By following same procedure as in Example 23, the following compoundswere prepared.

EXAMPLE 24

Starting compound: The compound of Reference Example 1 and the compoundof Reference Example 13

Desired compound:[[5-[[5-(4-Acetyl-3-hydroxy-2-propylphenoxy)pentyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid ##STR80##

Physicochemical properties:

(i) Melting point: 107° to 108° C.

(ii) Elemental analysis for C₂₀ H₂₆ N₂ O₅ S₃

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             51.04%   5.57%      5.95%  20.44%                                    Found    50.81%   5.64%      5.98%  20.40%                                    ______________________________________                                    

EXAMPLE 25

Starting compound: The compound of Reference Example 1 and the compoundof Reference Example 11

Desired compound:[[5-[[2-(4-Acetyl-3-hydroxy-2-propylphenoxy)ethyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid ##STR81##

Physicochemical properties:

(i) Melting point: 135° to 137° C.

(ii) Nuclear magnetic resonance spectra (DMSO-d₆, TMS, ppm)

0.98(t, 3H), 1.44(m, 2H), 2.60(s, 3H), 3,72(t, 2H), 4.16(d, 2H), 4.40(t,2H), 6.66 (d, 1H), 2.78(d, 1H), 12.81(s, 1H)

EXAMPLE 26

Starting compound: ##STR82## and Compound of Reference example 9

Desired compound:3-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]propionicacid ##STR83##

Physicochemical properties:

(i) Melting point 102° to 104° C.

(ii) Elemental analysis for C₁₉ H₂₄ N₂ O₅ S₃ :

    ______________________________________                                                     N      S                                                         ______________________________________                                        Calculated     6.14%    21.06%                                                Found          6.28%    21.03%                                                ______________________________________                                    

EXAMPLE 27

Starting compound: ##STR84##

Desired compound:5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-3-hydroxy-4-isothiazolcarboxylic acid ##STR85##

Physicochemical properties:

(i) Melting point 182° to 184° C.

(ii) Elemental analysis for C₁₈ H₂₁ NO₆ S₂ :

    ______________________________________                                                  C     H        H        S                                           ______________________________________                                        Calculated: 52.54%  5.14%    3.40%  15.58%                                    Found:      52.23%  4.96%    3.20%  15.48%                                    ______________________________________                                    

EXAMPLE 28 ##STR86##

To a solution of 0.28 g of4-[3-[(5-amino-1,3,4-thiadiazol-2-yl)thio]propoxy]-2-hydroxy-3-propylacetophenoneobtained in Example 2 dissolved in 5 ml of pyridine were added 0.28 g ofmono-p-methoxybenzyl malonate, 0.20 g of dicyclohexylcarbodiimide, and10 mg of p-toluenesulfonic acid, and the mixture obtained was stirredfor 3 hours at room temperature. Insoluble matters were filtered off andthe filtrate obtained was concentrated under reduced pressure. To theresidue thus formed was added 30 ml of water and the product wasextracted with 20 ml of toluene. The extract thus obtained was washedwith water, dried over anhydrous magnesium sulfate, and then the solventwas distilled off to provide a solid material. The solid material waswashed with methanol and dried to provide 0.25 g of p-methoxybenzyl3-[[5-[[3-(4-acetyl-3-hydroxy-2-porpylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]amino]-3-oxopropionate.

Melting point: 133° to 135° C.

Elemental analysis for C₂₇ H₃₁ N₃ O₇ S₂ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             56.53%   5.45%      7.32%  11.18%                                    Found    56.81%   5.46%      7.19%  10.96%                                    ______________________________________                                    

EXAMPLES 29 to 32

By following the same manner as in Example 28, the following compoundswere prepared.

EXAMPLE 29

Starting compound: Compound of Example 2 and ##STR87##

Desired compound: Ethyl4-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]amino]-4-oxobutyrate##STR88##

Physicochemical properties:

(i) Melting point: 129° to 131° C.

(ii) Elemental analysis for C₂₂ H₂₉ N₃ O₆ S₂ :

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              53.32%       5.90%    8.48%                                         Found     53.14        5.76     8.47                                          ______________________________________                                    

EXAMPLE 30

Starting compound: Compound of Example 9 and ##STR89##

Desired compound: p-Methyoxybenzyl3-[[5-[[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyl]-thio]-1,3,4-thiadiazol-2-yl]amino]-3-oxopropionate##STR90##

Physicochemical properties:

(i) Melting point 141° to 143° C.

(ii) Nuclear magnetic reasonance spectra (CDCl₃, TMS, ppm)

1.90(t,3H), 1.0-2.0(8H), 2.60(s,3H), 3.1-3.4(2H), 3.68(s,2H),3.80(s,3H), 3.9-4.2 (2H), 5.12(s,2H), 6.15-7.4(7H), 12.7(s,1H)

EXAMPLE 31

Starting compound: Compound of example 5 and ##STR91##

Desired compound:p-Methoxybenzyl-3-[[2-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]1H-1,2,4-triazol-3-yl]amino]-3-oxopropionate##STR92##

Physicochemical properties:

(i) Melting point: 151° to 153° C.

(ii) Elemental analysis for C₂₇ H₃₂ N₄ O₇ S:

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              58.26%       7.79%    10.07%                                        Found     58.24%       5.83%    9.90%                                         ______________________________________                                    

EXAMPLE 32

Starting compound: Compound of Example 2 and ##STR93##

Desired compound: p-Methoxybenzyl3-[[2-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]benzothiazol-6-yl]amino]-3-oxopropionate##STR94##

Physicochemical properties:

(i) Melting point: 103° to 105° C.

(ii) Elemental analysis for C₃₂ H₃₄ N₂ O₇ S₂ :

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              61.72%       5.50%    4.50%                                         Found     61.77%       5.44%    4.39%                                         ______________________________________                                    

EXAMPLE 33 ##STR95##

In a solution of 1.5 g of potassium hydroxide dissolved in 30 ml of 90%methanol was dissolved 0.9 g of p-methoxybenzyl ester obtained inExample 28 and the mixture was allowed to stand for 30 minutes at roomtemperature, 30 ml of water was added to the reaction mixture thusobtained. Then, methanol was distilled off from the reaction mixture andthe aqueous solution thus obtained was washed with 30 ml of ethylacetate, acidified with 10% hydrochloric acid, and then extracted with30 ml of ethyl acetate. The extract thus obtained was washed with water,dried over anhydrous magnesium sulfate, and then the solvent wasdistilled off to provide a solid material. The solid material was washedwith chloroform and dried to provide 0.5 g of3-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]amino]3-oxopropionicacid.

Melting point: 172° to 174° C.

Elemental analysis for C₁₉ H₂₃ N₃ O₆ S₂ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             50.32%   5.11%      9.26%  14.14%                                    Found    50.95%   5.01%      9.29%  13.93%                                    ______________________________________                                    

EXAMPLES 34 to 39

By following the same manner as Example 33, the following compounds wereprepared.

EXAMPLE 34

Starting compound: The compound of Example 29

Desired compound:4-[[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]amino]-4-oxobutyricacid ##STR96##

Physicochemical properties:

(i) Melting point: 204° to 206° C.

(ii) Elemental analysis for C₂₀ H₂₅ N₃ O₆ S₂ :

    ______________________________________                                                 C          H       N                                                 ______________________________________                                        Calculated:                                                                              51.38%       5.39%   8.99%                                         Found:     51.18%       5.37%   8.99%                                         ______________________________________                                    

EXAMPLE 35

Starting compound: The compound of Example 30

Desired compound:3-[[5-[[4-(4-Acetyl-3-hydroxy-2-propylphenoxy)butyl]thio]-1,3,4-thiadiazol-2-yl]amino]-3-oxopropionicacid. ##STR97##

Physicochemical property:

(i) Melting point: 168° to 170° C.

(ii) Elemental analysis for C₂₀ H₂₅ N₃ O₆ S₂ :

    ______________________________________                                                     C      H                                                         ______________________________________                                        Calculated     51.38%   5.39%                                                 Found          51.60%   5.68%                                                 ______________________________________                                    

EXAMPLE 36

Starting compound: The compound of Example 46

Desired compound:N-[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]oxamicacid ##STR98##

Physicochemical properties:

(i) Melting point: 172° to 175° C. (decompd.)

(ii) Elemental analysis for C₁₈ H₂₁ N₃ O₆ S₂ :

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              49.19%       4.82%    9.56%                                         Found     49.28%       4.80%    9.43%                                         ______________________________________                                    

EXAMPLE 37

Starting compound: Compound of Example 8

Desired compound:6-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-2-methylthio-4-pyrimidinecarboxylicacid ##STR99##

Physicochemical properties:

(i) Melting point: 125° to 128° C.

(ii) Nuclear magnetic reasonance spectra (TMS, CDCl₃ ppm)

0.92 (3H, t, J=6 Hz), 1.2-1.8(2H), 2.1-2.8 (4H), 2.55(3H, s), 2.59(3H,s), 3.3-3.6(2H) 4.1-4.3(2H), 6.42(1H, d, J=9 Hz), 7.5-7.7(2H)

EXAMPLE 38

Starting compound: Compound of Example 11

Desired compound:4-[[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]butyricacid ##STR100##

Physicochemical properties:

(i) Melting point: 100° to 101° C.

(ii) Elemental analysis for C₂₀ H₂₆ N₂ O₅ S₃ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             51.04%   5.57%      5.95%  20.44%                                    Found    51.18%   5.66%      5.74%  20.44%                                    ______________________________________                                    

EXAMPLE 39

Starting compound: Compound of Example 32

Desired compound:3-[[2-[[3-(4-Acethyl-3-hydroxy-2-propylphenoxy)propyl]thio]benzothiazol-6-yl]amino]-3-oxopropionicacid ##STR101##

Physicochemical Properties:

(i) Melting point: 148° to 150° C.

(ii) Elemental analysis for C₂₄ H₂₆ N₂ O₆ S₂ :

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              57.35%       5.21%    5.57%                                         Found     57.18%       5.19%    5.56%                                         ______________________________________                                    

EXAMPLE 40 ##STR102##

To a mixture of 4.2 g of ethyl[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]acetateobtained in Example 14 and 30 ml of methanol was added 20 ml of anaqueous solution of 5% sodium hydroxide and the mixture was stirred for30 minutes. Then, 30 ml of water was added to the reaction mixture andmethanol was removed under reduced pressure. The residue thus formed waswashed with ethyl acetate, acidified with diluted hydrochloric acid, andextracted with ethyl acetate. The extract was washed with water, driedover anhydrous magnesium sulfate, and concentrated under reducedpressure. The residue thus formed was recrystallized from 90% ethanol toprovide 3.07 g of[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid. The properties of the compound thus obtained were same as those ofthe compound obtained in Example 21.

EXAMPLES 41 to 45

By following the same procedure as Example 40, the following compoundswere prepared.

EXAMPLE 41

Starting compound: The compound of Example 15

Desired compound:5-[[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]valericacid ##STR103##

Physicochemical properties:

(i) Melting point 86° to 87° C.

(ii) Elemental analysis for C₂₁ H₂₈ N₂ O₅ S₃ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             52.04%   5.82%      5.78%  19.85%                                    Found    51.82%   6.02%      5.72%  19.96%                                    ______________________________________                                    

EXAMPLE 42

Starting compound: The compound of Example 16

Desired compound:6-[[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]hexanoicacid ##STR104##

Physicochemical properties:

(i) Melting point: 77° to 78° C.

(ii) Elemental analysis for C₂₂ H₃₀ N₂ O₅ S₃.1/2H₂ O

    ______________________________________                                                C          H        N                                                 ______________________________________                                        Calculated                                                                              52.15%       5.97%    5.53%                                         Found     52.14%       6.21%    5.33%                                         ______________________________________                                    

EXAMPLE 43

Starting compound: Compound of Example 17

Desired compound: Sodium2-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]propionicacid ##STR105##

Physicochemical properties:

(i) Oily product

(ii) Nuclear magnetic reasonance spectra (DMSO-d₆, TMS, ppm)

0.88(t,3H), 1.52(d,3H), 2.20(2H), 2.60(s,3H), 3,44(t,2H), 4.22(t,2H),6.66(d,1H), 7.84(d,1H), 12.8(s,1H),

EXAMPLE 44

Starting compound: Compound of Example 18

Desired compound:4-[[5-[[3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]valericacid ##STR106##

Physicochemical Properties:

(i) Oily product

(ii) Nuclear magnetic reasonance spectra (CDCl₃, TMS, ppm)

0.92(t, 3H), 1.49(d,3H), 2.12(t, 2H), 2.60 (s, 3H), 3.50(t,2H), 4.18(t,2H), 6.45(d,1H), 7.61(d,1H), 12.7(s,1H)

EXAMPLE 45

Starting compound: Compound of Example 50

Desired compound:[[5-[2-(4-Acetyl-3-hydroxy-2-propylphenoxy)acetamide]-1,3,4-thiadiazol-2-yl]thio]aceticacid ##STR107##

Physicochemical Properties:

(i) Melting point: 224° to 226° C.

(ii) Elemental analysis for C₁₇ H₁₉ N₃ O₆ S₂ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             47.99%   4.50%      9.88%  15.07%                                    Found    47.97%   4.41%      9.76%  14.94%                                    ______________________________________                                    

EXAMPLE 46 ##STR108##

To a solution of 0.4 g of4-[3-[(5-amino-1,3,4-thiadiazol-2-yl)thio]propoxy]-2-hydroxy-3-propylacetophenoneobtained in Example 2 dissolved in 10 ml of pyridine was added a mixtureof 0.2 g of ethyloxalyl chloride and 1 ml of toluene under cooling below-10° C. and then the resultant mixture was stirred for 30 minutes atroom temperature. The reaction mixture thus obtained was mixed with 50ml of water and extracted with 30 ml of ethyl acetate. The extract wassuccessively washed with water, 5% hydrochloric acid, and then water,dried, and then the solvent was distilled off under reduced pressure.The residue thus formed was applied to silica gel column chromatographyand eluted with a mixture of toluene and ethyl acetate (3:2) to provide0.3 g of ethylN-[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]oxamate.

Melting point: 146° to 147° C.

Elemental analysis for C₁₈ H₂₁ O₆ N₃ S₂ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             49.19%   4.82%      9.56%  14.59%                                    Found    49.28%   4.80%      9.43%  14.56%                                    ______________________________________                                    

EXAMPLE 47 ##STR109##

By following the same procedure as Example 22 using2-hydroxy-4-[2-hydroxy-3-[(5-mercapto-1,3,4-thiadiazol-2-yl)thio]propoxy]-3-propylacetophenoneobtained in Example 1 and bromoacetic acid as the starting materials,[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid was obtained. Melting point: 72° to 75° C.

Nuclear magnetic resonance spectra (CDCl₃. TMS internal standard, ppm)

0.92(t, 3H), 1.3-1.8(m, 2H), 2.54(s, 3H), 2.60(t, 2H), 3,60(t, 2H),4.04(s, 2H), 4.0-4.2(m, 2H), 4.2-4.6(m, 1H), 6.42(d, 1H), 7.60(d, 1H),12.7(s, 1H).

EXAMPLE 48 ##STR110##

To a solution of 0.42 g of 4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyricacid obtained in Reference Example 3 dissolved in 10 ml of pyridine wereadded 0.31 g of methyl [[5-amino-1,3,4-thiadiazol-2-yl)thio]acetate, 0.4g of dicyclohexylcarbodiimide, and 3 mg of p-toluenesulfonic acid andthe mixture was stirred for 3 hours at room temperature. Insolublematters were removed by filtration and the filtrate was concentrated.The solid residue thus formed was, without being purified, dissolved ina solution of 1 g of potassium hydroxide dissolved in 20 ml of 90%methanol and after filtering off insoluble matters, the filtrate wasallowed to stand for 30 minutes at room temperature. To the reactionmixture thus obtained was added 20 ml of water and then methanol wasdistilled off under reduced pressure. The aqueous solution thus obtainedwas washed with 20 ml of ethyl acetate. The aqueous solution wasacidified with 10% hydrochloric acid and extracted with ethyl acetate.The extract thus obtained was washed with water, dried over anhydrousmagnesium sulfate, and then the solvent was distilled off to provide 0.3g of[[5-[[4-(4-acetyl-3-hydroxy-2-propylphenoxy)butyrylamido]-1,3,4-thiadiazol-2-yl]thio]aceticacid.

Nuclear magnetic resonance spectra (CDCl₃, DMSO-d₆, ppm).

0.87(3H, t), 1.1-1.7(2H), 2.57(3H, s), 1.9-3.0(6H), 4,07(2H, s),4.11(2H, t), 6.61(1H, d), 7.78(1H, d), 12.80(1H, s)

EXAMPLE 49 ##STR111##

In a mixture of 1.5 ml of trifluoroacetic acid and 0.1 ml of anisole wasdissolved 100 mg of p-methoxybenzyl3-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1H-1,2,4-triazol-3-yl]amino]-3-oxopropionateobtained in Example 31 at 10° to 20° C. and after stirring the solutionthus obtained for 30 minutes, trifluoroacetic acid was distilled offunder reduced pressure. The residue thus formed was mixed with 20 ml ofwater and extracted with 20 ml of ethyl acetate. The extract was washedwith water, dried over anhydrous magnesium sulfate, and then the solventwas distilled off to provide a solid product. The solid product waswashed with methylene chloride and dried to provide 50 mg of3-[[5-[[-3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1H-1,2,4-triazol-3-yl]amino]-3-oxopropionicacid.

Melting point: 163° to 165° C.

Nuclear magnetic resonance spectra (CDCl₃ -DMSO-d₆ (10:1), TMS, ppm)

0.90(3H, t), 1.2-1.8(2H), 2.0-2.8(4H), 2.55(3H, s), 3.25(3H, t),3.48(2H, s), 4.17(2H, t), 6.44(1H, d), 7.61(1H, d), 12.68(1H, s).

EXAMPLE 50 ##STR112##

To a mixture of 0.7 g of (4-acetyl-3-hydroxy-2-propylphenoxy)acetic acidobtained in Reference Example 10, 0.6 g of ethyl[[5-amino-1,3,4-thiadiazol-2-yl]thio]acetate, 10 ml of pyridine, and 1mg of p-toluenesulfonic acid was added 0.57 g ofdicyclohexylcarbodiimide and the mixture was stirred for one hour atroom temperature. Insoluble matters were filtered off and the filtrateformed was concentrated under reduced pressure. To the residue thusformed was added ethyl acetate and the mixture was washed with dilutedhydrochloric acid, washed with diluted aqueous solution of sodiumhydrogen carbonate, washed with water, dried over anhydrous magnesiumsulfate, and concentrated under reduced pressure. The residue thusformed was recrystallized from 2-methoxyethanol to provide 0.8 g of[[5-[2-(4-acetyl-3-hydroxy-2-propylphenoxy)acetoamide]-1,3,4-thiadiazol-2-yl]thio]aceticacid.

Melting point: 183° to 184° C.

Elemental analysis for C₁₉ H₂₃ N₃ O₆ S₂ :

    ______________________________________                                               C      H          N        S                                           ______________________________________                                        Calculated                                                                             50.32%   5.11%      9.26%  14.14%                                    Found    50.47%   5.14%      9.24%  14.38%                                    ______________________________________                                    

EXAMPLE 51 ##STR113##

To a mixture of 0.5 g of[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]aceticacid, obtained in Example 22 0.23 g of dicyclohexylcarbodiimide, 0.14 gof 1-hydroxybenzotriazole, and 50 ml of tetrahydrofuran was added amixture of 0.27 g of N-methylhydroxylamine.hydrochloride, 0.3 g oftriethylamine, and 5 ml of N,N-dimethylformamide and the resultantmixture was stirred overnight at room temperature. Then, insolublematters were filtered off and the filtrate thus formed was concentratedunder reduced pressure. To the residue thus formed was added 100 ml ofethyl acetate and the mixture was washed with water, washed with adiluted aqueous solution of sodium hydrogencarbonate, and water, driedover anhydrous magnesium sulfate, and concentrated under reducedpressure. To the residue thus obtained was added ethyl acetate, theninsoluble materials were filtered off and the filtrate formed wasconcentrated. The residue thus obtained was recrystallized from amixture of toluene and n-hexane to provide 0.18 g of2-[[5-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-1,3,4-thiadiazol-2-yl]thio]-N-hydroxy-N-methylacetamide.

Melting point: 97° to 99° C.

Elemental analysis for C₁₉ H₂₅ N₃ O₅ S₃ :

    ______________________________________                                                     N                                                                ______________________________________                                               Calculated:                                                                           8.91%                                                                 Found:  9.06%                                                          ______________________________________                                    

EXAMPLE 52

    ______________________________________                                        (Tablet)                                                                      ______________________________________                                        Compound of Ex. 21       30     mg                                            Lactose                  104    mg                                            Corn starch              57     mg                                            Hydroxypropyl cellulose  4      mg                                            Calcium carboxymethyl cellulose                                                                        4      mg                                            Magnesium stearate       1      mg                                            total                    200    mg                                            ______________________________________                                    

After uniformly mixing 30 g of compound of Ex. 21, 104 g of lactose and57 g of corn starch, 40 ml of a 10% (w/w) aqueous solution ofhydroxypropyl cellulose was added to the mixture and the resultantmixture was granulated by a wet granulation method. The granules thusobtained were mixed with 4 g of calcium carboxymethyl cellulose and 1 gof magnesium stearate and the mixture was press-tableted into tablet(200 mg per tablet).

EXAMPLE 53

    ______________________________________                                        (Capsule)                                                                     ______________________________________                                        Compound of Ex. 21     30     mg                                              Crystalline cellulose  40     mg                                              Crystalline lactose    129    mg                                              Magnesium stearate     1      mg                                              total                  200    mg                                              ______________________________________                                    

The above components each in an amount 1000 times the foregoing amountwere mixed and then filled in gelatin capsule to provide capsules (200mg per capsule).

EXAMPLE 54 (Inhalation)

After dissolving 0.1 g of compound of Ex. 21 in about 90 ml of mixtureof ethanol, propylene glycol and purified water (30:10:60 in weightratio), the volume of the solution was adjusted to 100 ml using theaforesaid mixture and 10 ml each of the solution was filled in adefinite container followed by sealing to provide an inhalation.

What is claimed is:
 1. A heterocyclic compound represented by thefollowing formula (I) ##STR114## or a salt thereof; wherein R¹represents a lower alkanoyl group; R² represents a lower alkyl group; Arepresents a lower alkylene group which may be substituted by a hydroxygroup; Y represents an oxygen atom, a sulfur atom, a carbonyliminogroup, or an iminocarbonyl group;represents a pyrimidine ring; R³, R⁴and R⁵, which may be the same or different, each represents a hydrogenatom, a lower alkyl group, a group shown by the formula --A¹ --R⁶(wherein A¹ represents a lower alkylene group and R⁶ represents ahydroxy group, a mercapto group, a carboxy group or a loweralkoxycarbonyl group), a hydroxy group, a mercapto group, a lower alkoxygroup, a lower alkylthio group, a group shown by the formula --Y¹ --A²--R⁷ (wherein Y¹ represents an oxygen atom or a sulfur atom; A²represents a lower alkylene group, and R⁷ represents a carboxy group, alower alkoxycarbonyl group, a hydroxyaminocarbonyl group, a mono- ordi-lower alkylaminocarbonyl group or an N-loweralkyl-hydroxyaminocarbonyl group), an oxo group, a thioxo group, anamino group, a group shown by the formula --NH--R⁸ (wherein R⁸represents a carboxy lower alkyl group or a lower alkoxycarbonyl loweralkyl group), a group shown by the formula --NH--CO--R⁹ (wherein R⁹represents a carboxy-lower alkyl group, a lower alkoxycarbonyl loweralkyl group, a carboxy group or a lower alkoxycarbonyl group), a carboxygroup or a group shown by the formula --CO--R¹⁰ (wherein R¹⁰ representsa lower alkoxy group).
 2. A pharmaceutical composition useful as anantagonist of slow reacting substance of anaphylaxis (SRS-A) andcontaining as an individual adult dose amount, from 0.1 to 500 mg. of aheterocyclic ring compound represented by the formula (I) ##STR115## ora pharmaceutically acceptable salt thereof wherein R¹ represents a loweralkanoyl group; R² represents a lower alkyl group; A represents a loweralkylene group which may be substituted by a hydroxyl group; Yrepresents oxygen, sulfur, a carbonylimino group (--CONH--), or animinocarbonyl group (--NHCO--);represents a pyrimidine ring; R³, R⁴ andR⁵, which may be the same or different, each represents a hydrogen atom,a lower alkyl group, a group shown by the formula --A¹ --R⁶ (wherein A¹represents a lower alkylene group, R⁶ represents a hydroxyl group, amercapto group, a carboxy group or a lower alkoxycarbonyl group), ahydroxyl group, a mercapto group, a lower alkoxy group, a loweralkylthio group, a group shown by the formula --Y¹ --A² --R⁷ (wherein Y¹represents oxygen or sulfur, A² represents a lower alkylene group, R⁷represents a carboxy group, a lower alkoxycarbonyl group, ahydroxyaminocarbonyl group, a mono- or di-lower alkylaminocarbonyl groupor an N-lower alkyl-hydroxyaminocarbonyl group), an oxo group (═O), athioxo group (═S), an amino group, a group shown by the formula --NH--R⁸wherein R⁸ represents a carboxy lower alkyl group or a loweralkoxycarbonyl lower alkyl group), a group shown by the formula--NH--CO--R⁹ (wherein R⁹ represents a carboxy-lower alkyl group, a loweralkoxycarbonyl lower alkyl group, a lower alkoxypheny loweralkoxycarbonyl lower alkyl group, a carboxy group or a loweralkoxycarbonyl group), a carboxy group or a group shown by the formula--CO--R¹⁰ (wherein R¹⁰ represents a lower alkoxy group).
 3. Apharmaceutical composition containing a heterocyclic ring compoundrepresented by the general formula (I) ##STR116## or a pharmaceuticallyacceptable salt thereof wherein R¹ represents an acyl group; R²represents a lower alkyl group; A represents a lower alkylene groupwhich may be substituted by hydroxyl group; Y represents an oxygen atom,a sulfur atom, a carbonylimino group (--CONH--), or an iminocarbonylgroup (--NHCO--); represents a pyrimidine ring R³, R⁴ and R⁵, which maybe the same or different, each represents a hydrogen atom, a lower alkylgroup, a group shown by the formula --A¹ --R⁶ (wherein A¹ represents alower alkylene group, R⁶ represents a hydroxyl group, a mercapto group,a carboxy group or a lower alkoxycarbonyl group), a hydroxyl group, amercapto group, a lower alkoxy group, a lower alkylthio group, a groupshown by the formula --Y¹ --A² --R⁷ (wherein Y¹ represents an oxygenatom or a sulfur atom, A² represents a lower alkylene group, R⁷represents a carboxy group, a lower alkoxycarbonyl group, ahydroxyaminocarbonyl group, mono- or di-lower alkylaminocarbonyl groupor N-lower alkyl-hydroxyaminocarbonyl group), an oxo group (═O), athioxo group (═S), an amino group, a group shown by the formula --NH--R⁸(wherein R⁸ represents a carboxy lower alkyl group or a loweralkoxycarbonyl lower alkyl group), a group shown by the formula--NH--CO--R⁹ (wherein R⁹ represents a carboxy-lower alkyl group, a loweralkoxycarbonyl lower alkyl group, a lower alkoxyphenyl loweralkoxycarbonyl lower alkyl group, a carboxy group or a loweralkoxycarbonyl group), a carboxy group or a group shown by the formula--CO--R¹⁰ (wherein R¹⁰ represents a lower alkoxy group).
 4. Thepharmaceutical composition as claimed in claim 2, wherein saidpharmaceutical composition is capable of antagonizing the actions ofSRS-A.
 5. The heterocyclic compound or the salt thereof as claimed inclaim 1, wherein said heterocyclic compound is6-[[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]-2-methylthio-4-pyrimidinecarboxylicacid.
 6. The heterocyclic compound or the salt thereof as claimed inclaim 1, wherein Y is sulfur or a carbonylimino group and R³, R⁴, andR⁵, which may be the same or different, each is a hydrogen atom, a groupshown by the formula --A¹ --R⁶ (wherein, R⁶ is a hydroxy group); ahydroxy group, a mercapto group, a lower alkylthio group, a group shownby the formula --Y¹ --A² --R⁷ (wherein, Y¹ is sulfur; A² is a loweralkylene group; and R⁷ is a carboxy group, a lower alkoxycarbonyl group,or an N-lower alkyl-hydroxyaminocarbonyl group), an oxo group, a thioxogroup, an amino group, a group shown by the formula --NH--CO--R⁹, acarboxy group, or a group shown by the formula --CO--R¹⁰ wherein R⁹ andR¹⁰ are as indicated.
 7. The heterocyclic compound or the salt thereofas claimed in claim 1, wherein R¹ is an acetyl group; R² is a propylgroup, A is an alkylene group having 1 to 5 carbon atoms; Y is a sulfuratom; Het is a pyrimidine ring; and R³, R⁴, and R⁵, which may be thesame or different, each is a hydrogen atom, a hydroxy group, a mercaptogroup, a lower alkylthio group, an amino group, a carboxy group, or agroup shown by the formula --COR¹⁰.
 8. The heterocyclic compound or thesalt thereof as claimed in claim 1, wherein said heterocyclic compoundis6-[[3-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propyl]thio]2-methylthio-4-pyrimidinecarboxylicacid.
 9. The pharmaceutical composition as claimed in claim 2 whereinsaid pharmaceutical composition is capable of inhibiting the productionand release of SRS-A.
 10. A method of antagonizing the action of SRS-Ain a host which comprises administering to said host a pharmaceuticallyeffective amount of the composition of claim
 2. 11. A method ofinhibiting the production and release of SRS-A in a host which comprisesadministering to said host a pharmaceutically effective amount of thecomposition of claim 2.